Loading…

Assessment of the feed additive consisting of Lentilactobacillus buchneri ATCC PTA‐6138 for all animal species for the renewal of its authorisation (Pioneer Hi‐Bred International, Inc.)

Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for renewal of Lentilactobacillus buchneri ATCC PTA‐6138 as a technological additive (functional group: silage additives) for all animal species. The applicant has pr...

Full description

Saved in:
Bibliographic Details
Published in:EFSA journal 2024-05, Vol.22 (5), p.e8787-n/a
Main Authors: Bampidis, Vasileios, Azimonti, Giovanna, Bastos, Maria de Lourdes, Christensen, Henrik, Durjava, Mojca, Dusemund, Birgit, Kouba, Maryline, López‐Alonso, Marta, López Puente, Secundino, Marcon, Francesca, Mayo, Baltasar, Pechová, Alena, Petkova, Mariana, Ramos, Fernando, Villa, Roberto Edoardo, Woutersen, Ruud, Saarela, Maria, Alija‐Novo, Natalia, Anguita, Montserrat, Bozzi Cionci, Nicole, Brozzi, Rosella, García‐Cazorla, Yolanda, Innocenti, Matteo Lorenzo, Revez, Joana
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for renewal of Lentilactobacillus buchneri ATCC PTA‐6138 as a technological additive (functional group: silage additives) for all animal species. The applicant has provided evidence that the additive currently on the market complies with the existing terms of the authorisation. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) concluded that the additive remains safe for all animal species, consumers and the environment. Regarding user safety, the additive should be considered as a skin and respiratory sensitiser. No conclusions could be drawn on the eye irritancy potential of the additive. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.
ISSN:1831-4732
1831-4732
2314-9396
DOI:10.2903/j.efsa.2024.8787